{'fraction_non_alphanumeric': 0.023323615160349854, 'fraction_numerical': 0.01239067055393586, 'mean_word_length': 5.356481481481482, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Gastrointestinal and Nutritional Complications of Human Immunodeficiency Virus Infection

A. Epidemiology of Pediatric HIV 
As of December 2007, the World Health Organization (WHO) estimated that 2.5 million children had HIV worldwide1. Approximately 420,000 children become newly infected with HIV annually, mainly through mother-to-child transmission (MTCT). This makes pediatric HIV a leading cause of morbidity and mortality1. Antiretroviral therapy (ART) has prevented MTCT and has lowered the prevalence of perinatal HIV in developed countries. Increased use of prophylactic medications in developing nations is helping to contain the epidemic in those countries as well1. However, pediatric HIV in many countries continues to be a widespread public health problem. 
 
Maternal HIV status and death, as well as childhood undernutrition, independently affect childhood mortality. Worldwide, HIV infection is associated with greater child mortality over standard risk by 2 years of age2. In developing nations, children with HIV have the same morbidities as non-infected children, yet the rate of disease morbidity is greater with an increased likelihood for progression to AIDS. Increased availability and effectiveness of ART, as well as improved methods of detecting HIV in women and children, will have the greatest impact on outcomes until a vaccine is developed.